| 证券代码 | MBVX.O |
| 证券名称 | MabVax Therapeutics Holdings Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2000-08-11 |
| 首发价格(元) | 7 USD |
| 首发数量(股) | 5000000 |
| 首发募资额(元) | 35,000,000.00 USD |
| 首发主承销商 | Lehman Brothers Inc,UBS Warburg LLC |
| 货币单位 | USD |
| 公司名称 | MabVax Therapeutics Holdings, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 11535 Sorrento Valley Road, Suite 400, San Diego, California, USA |
| 成立日期 | 1988 |
| 董事会主席 | J. David Hansen |
| 公司属地 | United States 美国 |
| 公司网址 | www.mabvax.com |
| 电话 | +1 (858) 259-9405 |
| 传真 | - |
| 公司简介 | MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with their proprietary vaccines. MabVax's lead development program is centered around their HuMab-5B1 antibody, which is fully human and discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers, and also expressed in significant percentages on small cell lung cancer, stomach, colon and other cancers, making the antibody potentially broadly applicable to many types of cancers. They have other antibody candidates that are also in preclinical development. |